Use of Durvalumab in the treatment of unresectable stage III NSCLC

29 June 2021, 16.30 - 17.30

Join this webinar to hear Dr Charlotte Milner-Watts update on the use of Durvalumab in the treatment of unresectable stage III NSCLC. Covering specifically

  • Therapeutic indication, rationale, schedule
  • PACIFIC – key trial data
  • Toxicity management
  • Follow up
  • Case studies
We will welcome your questions for the Q & A at the end of the session

Our webinars are for healthcare professionals only.

Register Now


Dr Charlotte Milner-WattsDr Charlotte Milner-Watts

I am a clinical fellow in the lung unit at the Royal Marsden Hospital. I treat patients with lung cancer, mesothelioma and thymic carcinoma, in the standard of care, clinical trial and compassionate/expanded access settings. I have experience in the use of chemotherapy, immunotherapy and targeted therapy. I recruit patients to clinical trials and manage their care as they proceed on study. I actively participate in research meetings and the MDT. I have a particular interest in molecular-driven lung cancer and participate in the presentation and review of molecular results at our Genomics Tumour Advisory Board.

Paula ShepherdPaula Shepherd

LCNUK Committee member. Paula Shepherd currently works as a Respiratory and Lung Cancer CNS at Aintree University Hospital. She qualified as an RGN in 2001 and her main experience has been gained within respiratory medicine, with a particular interest being lung cancer. She has been a Respiratory CNS since 2009 and began her role as a Lung Cancer CNS in 2011, moving to her current Trust in 2013. Paula has completed numerous role specific degree modules previously and became a Non Medical prescriber in March 2017. Her role as a Lung Cancer CNS involves supporting patients throughout their pathway from pre-diagnosis through to palliative care.

Thank you to our webinar sponsor AstraZeneca


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

With its global headquarters in Cambridge, AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, we undertook 201 trials in the UK, involving 376 centres and over 7,000 patients. 

For more information, please visit and follow us at @AstraZenecaUK

Join Lung Cancer Nursing UK

Be a member of a dynamic and cohesive forum of lung cancer nurse specialists (LCNS) working throughout the UK. Membership costs just £30 per year and is open to any specialist nurse who spends more than 50% of their working week or clinical activities in caring for patients with lung cancer.

Join Now

LCNUK Webinar Series

Our series of webinars will be continuing throughout 2021.

We hope you can join us on online.

Register for Upcoming Webinars